Fordham 2016: Will purposive construction of Swiss-type claims save second-medical use patents? By Annsley Merelle Ward on Tuesday, April 05, 2016 AmeriKat cost of medicines EPC 2000 event report Fordham 2016 incentivization patent enforcement Second medical use skinny label Swiss claims +
Letter from AmeriKat: Will narrowing innovator-generic price gap change IP law? By Annsley Merelle Ward on Monday, March 16, 2015 AmeriKat cost of medicines economics of pharmaceutical IP generic drug applications generic pharma products hatch-waxman innovator IP market United States IP system +
The ethics of biotech patenting: a dialogue about monopolies, human dignity and the cost of medicines By Suleman Ali on Sunday, January 11, 2015 biotech patents cost of medicines ethics human dignity +